We also verified whether the observed pro-apoptotic effects of the combination depend on some clinico-hematological characteristics of our CLL patients, such as sex, stage of the disease according to Rai, CD5+/CD19+ lymphocytes count, WBC, ALC, cytogenetic prognostic factors, CD38 and ZAP-70 expression status, and LDH or B2M concentrations. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.